Literature DB >> 2578546

Idiotype connectance in the immune system. II. A heavy chain variable region idiotope that dominates the antibody response to the p-azobenzenearsonate group is a minor idiotope in the response to trinitrophenyl group.

P V Hornbeck, G K Lewis.   

Abstract

We describe the recurrence of a cross-reactive idiotope (CRIAD8) in antibody responses to different epitopes, and explore factors leading to its dominance in some responses, but not others. Serological and genomic DNA analyses showed that CRIAD8 is a marker of the CRIa heavy chain variable region (VH) that encodes the majority of anti-p-azobenzenearsonate (anti-ABA) antibodies. The independence of CRIAD8 from any particular light chain or antigen specificity was underscored by the fact that we could isolate hybridomas that secrete antitrinitrophenyl (TNP) antibodies expressing CRIAD8, with lambda 1 light chains. CRIAD8 is dominant in anti-ABA responses, recurrent but nondominant in anti-TNP and anti-chicken gammaglobulin responses, and is virtually absent in other antihapten responses, including that to p-azobenzenephosphonate (ABP), which contains an ABA-cross-reactive component (approximately 5-40%). Dominance in the anti-TNP response could not be achieved by immunization with doubly haptenated TNP-ABA-KLH (keyhole limpet hemocyanin), where the anti-ABA response was dominated by CRIAD8. These observations suggest that, while the CRIAD8 VH region is necessary for idiotypic dominance, it is not sufficient. Apparently, an additional specificity is required. Since immunization with ABA calls up anti-ABP antibodies that express CRIAD8, but not vice versa, it is possible that the additional specificity is ABA itself. This possibility imposes a new constraint on the specificity of the putative idiotype-specific regulation that may establish dominance in the CRIa system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578546      PMCID: PMC2187547          DOI: 10.1084/jem.161.1.53

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  45 in total

1.  Sharing of an idiotypic marker by monoclonal antibodies specific for distinct regions of hen lysozyme.

Authors:  D W Metzger; A Miller; E E Sercarz
Journal:  Nature       Date:  1980-10-09       Impact factor: 49.962

2.  Immunoglobulin idiotype and anti-anti-idiotype utilize the same variable region genes irrespective of antigen specificity.

Authors:  M N Margolies; L J Wysocki; V L Sato
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

3.  Idiotypes of anti-myoglobin antibodies: shared idiotypes among monoclonal antibodies to distinct determinants of sperm whale myoglobin.

Authors:  Y Kohno; I Berkower; J Minna; J A Berzofsky
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

4.  Structural diversity among anti-p-azophenylarsonate monoclonal antibodies from A/J mice; comparison of Id- and Id+ sequences.

Authors:  M N Margolies; A Marshak-Rothstein; M L Gefter
Journal:  Mol Immunol       Date:  1981-12       Impact factor: 4.407

5.  The genetic basis of antibody production: the dominant anti-arsonate idiotype response of the strain A mouse.

Authors:  M Siekevitz; M L Gefter; P Brodeur; R Riblet; A Marshak-Rothstein
Journal:  Eur J Immunol       Date:  1982-12       Impact factor: 5.532

6.  The strain A anti-p-azophenylarsonate major cross-reactive idiotypic family includes members with no reactivity toward p-azophenylarsonate.

Authors:  L J Wysocki; V L Sato
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

7.  The genetic basis of antibody production: a single heavy chain variable region gene encodes all molecules bearing the dominant anti-arsonate idiotype in the strain A mouse.

Authors:  M Siekevitz; S Y Huang; M L Gefter
Journal:  Eur J Immunol       Date:  1983-02       Impact factor: 5.532

8.  Quantitative investigations of idiotypic antibodies. VI. Idiotypic specificity as a potential genetic marker for the variable regions of mouse immunoglobulin polypeptide chains.

Authors:  M G Kuettner; A L Wang; A Nisonoff
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

9.  Idiotype-anti-idiotype network. II. Activation of silent clones by treatment at birth with idiotypes is associated with the expansion of idiotype-specific helper T cells.

Authors:  L J Rubinstein; M Yeh; C A Bona
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

10.  Regulation of azophenylarsonate-specific repertoire expression. 1. Frequency of cross-reactive idiotype-positive B cells in A/J and BALB/c mice.

Authors:  N H Sigal
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

View more
  6 in total

1.  Site-directed mutagenesis of an invariant amino acid residue at the variable-diversity segments junction of an antibody.

Authors:  J Sharon; M L Gefter; T Manser; M Ptashne
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

2.  Molecular characterization of monoclonal CRIA-positive anti-arsonate antibodies derived from idiotype-negative mice bearing a light chain polymorphism.

Authors:  J Tassignon; M Brait; J Ismaili; J Urbain; P Gottlieb; A Brown; C A Hasemann; J D Capra; K Meek
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

3.  Extra- and intracellular metabolite concentrations for murine hybridoma cells.

Authors:  G Schmid; H W Blanch
Journal:  Appl Microbiol Biotechnol       Date:  1992-02       Impact factor: 4.813

4.  Effects of CO2 and osmolality on hybridoma cells: growth, metabolism and monoclonal antibody production.

Authors:  V M Dezengotita; R Kimura; W M Miller
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

5.  Idiotypic network connectivity and a possible cause of myasthenia gravis.

Authors:  D S Dwyer; M Vakil; J F Kearney
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

6.  A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling.

Authors:  J M Burns; R C Gallo; A L DeVico; G K Lewis
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.